The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. (31st March 2016)

• Record Type: Journal Article
• Authors: Lee, Yung‐Chin; Juan, Yung‐Shun; Liu, Chia‐Chu; Bao, Bo‐Ying; Wang, Chii‐Jye; Wu, Wen‐Jeng; Huang, Chun‐Nung; Huang, Shu‐Pin
• Is Part Of: BJU international. Volume 118:Number 2(2016:Jul.)
• Page Start: 313
• Page End: 319
• Publication Date: 2016-03-31
• Subjects: endothelial nitric oxide synthase G894T -- gene polymorphisms -- α1‐blocker -- benign prostatic hyperplasia related lower urinary tract symptoms; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.13468
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objective: To prospectively investigate the association of endothelial nitric oxide synthase ( eNOS ) G894T gene polymorphism with responsiveness to a selective α1 ‐blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms (BPH/LUTS), as nitric oxide has recently gained increasing recognition as an important neurotransmitter of functions in the lower urinary tract. Patients and Methods: In all, 136 men with BPH/LUTS were recruited from urology outpatient clinics in a university hospital. Oral therapy with doxazosin gastrointestinal therapeutic system (GITS) 4 mg once‐daily was given for 12 weeks. The drug efficacy was assessed by the changes from baseline in the total International Prostate Symptom Score (IPSS), maximum urinary flow rate ( Q max ) and post‐void residual urine volume (PVR) at 12 weeks of treatment. The 'responders' to doxazosin GITS were defined as those who had a total IPSS decrease of >4 points from baseline. eNOS G894T polymorphism was determined using the polymerase chain reaction‐restriction fragment length polymorphism method. Results: Patients had statistically significant improvements in total IPSS, quality of life score, and Q max ( P < 0.01) after a 12‐week period of treatment. Using multiple logistic regression analysis adjusted for age and IPSS, our results showed that being a eNOS 894T allele carrier was an independent risk factor for being a drug non‐responder ( P = 0.03, odds ratio 4.19). Moreover, a decreased responder rate ( P = 0.01), as well as the lower improvements in IPSS ( P = 0.02) and Q max ( P = 0.03) were significantly associated with increment in the T allele number. Conclusions: The presence of the eNOS 894T allele had a significantly negative impact on responsiveness to a selective α1 ‐blocker in BPH/LUTS treatment, suggesting that eNOS G894T gene polymorphism may be a genetic susceptibility factor for α1 ‐blocker efficacy in men with BPH/LUTS.